Figure 5
RBP2 enhanced tumorigenicity in vivo. (a) RBP2 overexpressing cells or mock transfected cells were implanted into immunodeficient mice. Tumor volume in mm3 was measured for 4 weeks as indicated and RBP2 overexpressing cells enhanced tumor progression (P<0.05). (b) Upon killing, tumor weights were measured and the RBP2-injected group had bigger tumors (P<0.01). (c) Ki67 and (d) TUNEL staining of the xenografts indicate no change in proliferation rates but fewer apoptotic cells in the RBP2 group than in the control group.
